Invention Grant
- Patent Title: Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
-
Application No.: US15751472Application Date: 2016-07-26
-
Publication No.: US10709775B2Publication Date: 2020-07-14
- Inventor: Mathilde Dusseaux
- Applicant: CELLECTIS
- Applicant Address: FR Paris
- Assignee: Cellectis
- Current Assignee: Cellectis
- Current Assignee Address: FR Paris
- Agency: Arrigo, Lee, Guttman & Mouta-Bellum LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6524956 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5c8ad74b
- International Application: PCT/EP2016/067800 WO 20160726
- International Announcement: WO2017/025323 WO 20170216
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K14/705 ; C07K16/28 ; A61K39/395 ; C12N5/0783 ; A61P35/00
Abstract:
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Public/Granted literature
- US20180236053A1 CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING CD38 ANTIGEN AND FOR CD38 GENE INACTIVATION Public/Granted day:2018-08-23
Information query
